This is a United States plan; I appreciate the answer is jurisdiction-specific.
The figures are clear enough; the question is what they mean and what they do not.
I can supply the numbers if the specifics change the answer.
What would I need in addition before this supported a decision?
Section 503A is an exemption, not an approval, and it is conditional on four things. A patient-specific prescription; a licensed pharmacist or physician doing the compounding in a licensed facility; bulk substances that either have a USP monograph, appear on the FDA's 503A bulks list, or are components of an approved drug, each with a certificate of analysis from a registered supplier; and the preparation must not be essentially a copy of a commercially available drug. That last condition is the one that moves: it turns on the shortage list, and what was lawful under 503A while a product was in shortage stops being lawful when the shortage is resolved. None of the four requires the finished preparation to be tested, which is the gap that independent assay fills.
Answering this needs the jurisdiction, since this two-tier structure is a feature of one national framework and does not translate directly elsewhere.
Outsourcing facilities may produce without a patient-specific prescription, register federally, are inspected on a risk-based schedule and are subject to current good manufacturing practice.
Adverse event reporting obligations attach to the outsourcing category and not to the patient-specific one, which is a real difference in the information that exists about what a facility produces.
Inspection findings for registered facilities are published and are directly checkable for a named facility.
Nothing here is legal or medical advice.
The category tells you which standards apply, not how good the preparation is.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThis is a regulatory question with a clean answer, unusually for this family.
Neither category produces an approved product. Both operate outside the marketing-authorisation framework, and the difference is in the manufacturing standards applied, not in approval status.
A facility that will not say which category it operates under has told you something, and the registration lists will tell you the rest.
The two-tier structure separating patient-specific compounding from outsourcing facilities is established in federal law and the registration lists are published.
This structure is jurisdiction-specific. It does not describe your country unless it does.
Start with which category a facility is registered under, because it is a matter of public record and it tells you what it can legally do.
Registration status is published and searchable. Checking it takes a minute and is the single most useful verification available in this whole area.
Beyond-use dating differs by category and by the preparation environment, and an unusually long date on a compounded sterile preparation is worth asking about.
Current good manufacturing practice applies to the outsourcing category and not to patient-specific compounding, which is the substantive regulatory difference.
Inspection findings are public for registered facilities. Read them.
edited 8 May 2025 by meniscus_film — updated for the 2026 guidance change
The relevant point is that the heavier-obligation category is inspected against manufacturing standards and the lighter one is not.
The practical consequences: an outsourcing facility can supply office stock and distribute at volume; a patient-specific compounder cannot do either without stepping outside its category.
Adverse event reporting obligations attach to registered outsourcing facilities and are the basis for what public information exists.
A registration category describes obligations, not the quality of any particular preparation.
Neither category is an approved product. That is unchanged by registration.
Registration status is published and checkable, which makes this one of the few claims in this space that can be verified directly.
Patient-specific compounding requires a prescription for a named individual, is regulated primarily at state level, and is not subject to current good manufacturing practice requirements.
The statutory basis for the 503A/503B distinction is sections 503A and 503B of the US Federal Food, Drug, and Cosmetic Act as amended by the Drug Quality and Security Act of 2013, and the FDA’s guidance documents on each are the authoritative description of what is permitted.
Neither category yields an approved product, and the distinction is often blurred in marketing.
Check the registration list. It takes a minute and it is the one verifiable claim here.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.